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Background: Retinoic acid receptor alpha (RARα) plays an essential role in the regulation of many biological
processes, such as hematopoietic cell differentiation, while abnormal RARα function contributes to the
pathogenesis of certain diseases including cancers, especially acute promyelocytic leukemia (APL). Recently,
oridonin, a natural diterpenoid isolated from Rabdosia rubescens, was demonstrated to regulate RARα by
increasing its protein level. However, the underlying molecular mechanism for this action has not been
fully elucidated.
Methods: In the APL cell line, NB4, the effect of oridonin on RARα protein was analyzed by western blot and
real-time quantitative RT-PCR analyses. Flow cytometry was performed to detect intracellular levels of reactive
oxygen species (ROS). The association between nuclear factor-kappa B (NF-κB) signaling and the effect of
oridonin was assessed using specific inhibitors, shRNA gene knockdown, and immunofluorescence assays. In
addition, primary leukemia cells were treated with oridonin and analyzed by western blot in this study.
Results: RARα possesses transcriptional activity in the presence of its ligand, all-trans retinoic acid (ATRA).
Oridonin remarkably stabilized the RARα protein, which retained transcriptional activity. Oridonin also moderately
increased intracellular ROS levels, while pretreatment with the ROS scavenger, N-acetyl-l-cysteine (NAC), dramatically
abrogated RARα stabilization by oridonin. More intriguingly, direct exposure to low concentrations of H2O2 also
increased RARα protein but not mRNA levels, suggesting a role for ROS in oridonin stabilization of RARα protein. Further
investigations showed that NAC antagonized oridonin-induced activation of NF-κB signaling, while the
NF-κB signaling inhibitor, Bay 11–7082, effectively blocked the oridonin increase in RARα protein levels. In line with this,
over-expression of IκΒα (A32/36), a super-repressor form of IκΒα, or NF-κB-p65 knockdown inhibited oridonin or H2O2-
induced RARα stability. Finally, tumor necrosis factor alpha (TNFα), a classical activator of NF-κB signaling, modulated
the stability of RARα protein.
Conclusions: Oridonin stabilizes RARα protein by increasing cellular ROS levels, which causes activation of the
NF-κB signaling pathway.
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Retinoid receptors are retinoid ligand-activated tran-
scription factors that are divided into retinoic acid re-
ceptors (RARs) and retinoid X receptors (RXRs). Both
RARs and RXRs have three isoforms, including RARα/β/
γ and RXRα/β/γ. These proteins are encoded by distinct
loci and exist as alternatively spliced variants [1]. Active
retinoid receptors consist of RAR/RXR heterodimers,
which activate the transcription of many target genes by
binding retinoic acid responsive elements in promoter
and/or enhancer regions. They exert many essential and
potent biological functions with respect to the regulation
of cell proliferation, differentiation, apoptosis, and au-
tophagy [2-4]. Accordingly, retinoids and their receptors
are also widely involved in the pathogenesis of many dis-
eases, especially cancers [5]. A typical example is that of
acute promyelocytic leukemia (APL), a unique subtype
of acute myeloid leukemia (AML). Almost all APL pa-
tients carry chromosome translocations involving RARα,
most of which are t(15;17). This causes fusion of the
promyelocytic leukemia (PML) gene to the RARα gene
and expression of a PML-RARα fusion gene, leading to
impaired retinoid signaling and pathogenesis of APL.
Importantly, all-trans retinoic acid (ATRA) and arsenic
trioxide target the PML-RARα fusion protein to induce
differentiation and/or apoptosis of leukemia-initiating cells
[6-10]. Besides APL, some other types of cancer also
present with aberrant expression of RARs. For example,
the expression of RARα/β and RXRα/β are down-
regulated in pancreatic ductal adenocarcinoma, which is
associated with poor patient survival outcomes [11].
The mechanisms regulating the expression of RARs
are not fully understood. ATRA can directly target
RARα to ubiquitin-proteasome degradation in APL and
non-APL cells [12], while activation of c-Jun N-terminal
kinase (JNK) can contribute to RAR dysfunction by
phosphorylating RARα at Thr181, Ser445, and Ser461.
This induces RAR degradation through the ubiquitin-
proteasome pathway, pointing to JNK as a key mediator
of aberrant retinoid signaling in lung cancer cells [13].
Additionally, JNK activation by oxidative stress also sup-
presses retinoid signaling through proteasomal degrad-
ation of RARα in hepatic cells [14]. More recently,
pharicin B, a novel natural ent-kaurene diterpenoid de-
rived from Isodon pharicus leaves, was reported to rap-
idly stabilize RARα protein in various AML cell lines
and primary leukemic cells from AML patients [15].
Oridonin, another ent-kaurene diterpenoid isolated
from Rabdosia rubescens, has a variety of biological
effects, such as anti-inflammatory, anti-viral, and anti-
bacterial functions, as well as anti-tumor effects on dif-
ferent cancers including liver [16], prostate [17], breast
[18], and leukemia [19]. Accumulating evidence illus-
trates that oridonin has extensive anti-tumor effectsinvolving regulation of the cell cycle, apoptosis, autophagy,
and differentiation [20-22]. Previously, we reported that
oridonin could induce ROS-initiated apoptosis and en-
hance ATRA-induced differentiation in APL cells. Inter-
estingly, the differentiation-enhancing effect of oridonin
was accompanied by increased levels of RARα protein
[23]. In this work, we further investigated the mechanisms
underlying oridonin stabilization of RARα protein.
Methods
Cells
NB4/GFP and NB4/GFP-MAD cells were generous gifts
from F. Besancon (Hôpital St. Louis, Paris, France). Con-
struction of the two cell lines was described previously
by Komura et al. [24]. NB4, NB4/GFP, and NB4/GFP-
MAD cells were cultured in RPMI 1640 medium
(Sigma-Aldrich, St. Louis, MO, USA), supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS;
HyClone, Logan, UT, USA). COS-7 and 293 T cells were
cultured in Dulbecco’s modified Eagle’s medium (Life
Technologies, USA), supplemented with 10% FBS in a
humidified incubator at 37°C with 5% CO2/95% air (v/v).
Reagents and antibodies
Oridonin (purity >99.5%) was purchased from Xi’an
Haoxuan Biotechnique, China. It was dissolved in di-
methyl sulfoxide (DMSO) at a stock concentration of
10 mM and stored at −20°C. Both N-acetyl-l-cysteine
(NAC) and ATRA were purchased from Sigma-Aldrich.
Recombinant human tumor necrosis factor (TNFα) was
obtained from Peprotech (Rocky Hill, NJ, USA). Cyclo-
heximide was purchased from Sigma-Aldrich. ERK in-
hibitor PD98059, p38 inhibitor SB203580, JNK inhibitor
SP600125, and NF-κB inhibitor Bay 11–7082 were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). When cells were treated with these reagents,
matching concentrations of vehicle were used as the
control and the final concentration of DMSO was kept
at or below 0.1% in all experiments.
Antibodies recognizing p65, IκBα, and RARα were pur-
chased from Santa Cruz Biotechnology. Antibodies recog-
nizing phospho-IκBα (Ser32/Ser36), phospho-p65, IκB
kinase beta (IKKβ), phospho-IKKα/β, phospho-ERK1/
ERK2, ERK1/ERK2, phospho-p38, p38, phospho-JNK, and
JNK were purchased from Cell Signaling Technology
(Beverly, MA, USA).
Western blot
Equal amounts of protein extracts were loaded onto a
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE) system, electrophoresed, and trans-
ferred to nitrocellulose membranes (Amersham). After
blocking with 5% (w/v) nonfat milk in PBS for 2 hours
at room temperature, the membranes were incubated
Cao et al. BMC Cancer  (2015) 15:248 Page 3 of 12with specific antibodies overnight, followed by incuba-
tion with horseradish peroxidase-linked secondary anti-
body (Cell Signaling Technology) for 1 hour at room
temperature. The signals were detected by the chemilu-
minescence phototope-HRP kit (Millipore), according to
the manufacturer’s instructions. β-actin was probed as
an internal control. All experiments were repeated three
times, and similar results were obtained.
RNA extraction and real-time quantitative RT-PCR
The cells were lysed, and total RNA was isolated using a
TRIzol kit (Invitrogen). Then, the RNA was treated with
DNase (Promega). Complementary DNA was synthe-
sized according to the manufacturer’s instructions. Real-
time quantitative RT-polymerase chain reactions (PCRs)
for RARα, retinoic acid receptor beta (RARβ), CCAAT/
enhancer binding protein-beta (C/EBP-β), retinoic acid-
induced genes E (RIG-E) and interferon regulatory factor 1
(IRF-1), were performed with SYBR Green PCR Master
Mixture Reagents (Applied Biosystems) on the Applied Bio-
systems 7300 real-time RT-PCR system. The specific
primers used as follows: 5′-TCTGTGAGAAACGACCG
AAAC-3′ and 5′-TGAGGGTGGT GAAGCCG-3′ for
RARα gene, 5′-AGTTTGATGGAGTTGGG TGGAC-3′
and 5′-GATGCTGCCATTCGGTTTG-3′ for RARβ, 5′-T
CAGCACCC TGCGGAACTT-3′ and 5′-AAGTGCCCCA
GTGCCAAAG-3′ for C/EBPβ, 5′-AGG GAGACCGTG
TCAGTA GGG-3′ and 5′-CGGAAGTGGCAGAAACC
CC-3′ for RIG-E, and 5′-ATGAGACCCTGGCTAGA
G-3′ and 5′-AAGCATCCGGTAC ACTCG-3′ for IRF-1.
The primers were synthesized by Sangon Biotech
(Shanghai, China). All experiments were performed in
triplicate. Data were normalized to the housekeeping
gene β-actin, and the relative abundance of transcripts
was calculated by the comparative ΔΔCT method.
Redox diagonal electrophoresis
The samples were prepared in 1× SDS sample buffer with-
out any reducing agent and loaded onto 10% SDS-PAGE
gels. After the first dimension, non-reducing electrophor-
esis, the entire lane containing the separated proteins was
excised and soaked for 20 min in SDS sample buffer con-
taining 100 mM dithiothreitol to reduce any disulfide
bonds present between proteins or within proteins. The
gel lane was then rotated 90 degrees and placed horizon-
tally on top of a large-format, 1.5-mm-thick 10% acryl-
amide gel. Under these conditions, the proteins that do
not form disulfide bond electrophorese identically in both
dimensions and form a diagonal after the second di-
mension. In contrast, proteins that contain intra-chain
disulfide bond lie above this diagonal, while those that
form inter-disulfide bond fall below the diagonal. Fi-
nally, immunoblot was performed to identify the dots
containing RARα.Detection of intracellular ROS level
The cells were incubated with 2′,7′-dichlorodihydrofluor-
escein diacetate (H2DCFDA) (Molecular Probes/Invitro-
gen) in PBS for 30 min at 37°C while protected from light.
The fluorescence intensity, which resulted from the oxida-
tion of the dye, was measured by fluorescence-activated
cell sorting (FACS) to determine the level of ROS. The ex-
periments were performed in triplicate.
Plasmid construction and transfection
Pairs of complementary shRNA oligonucleotides against
catalase (5′-AGATGATCTACT CAGAAAT-3′), p65
(5′-GATGAGATCTTCCTACTGT-3′), and non-targeting
control NC (5′-TCCCGTGAATTGGAATCCT-3′) were
synthesized by Sangon Biotech (Shanghai, China),
annealed, and ligated into the pSIREN-RetroQ Vector
(Clontech Laboratories) between the BamHI and EcoRI
sites. A full-length cDNA of human RARα was amplified
from NB4 cells by PCR and cloned into the virus expres-
sion vector, pMSCV-puro (Clontech Laboratories). shRNA/
cDNA-carrying retroviruses were produced in 293 T cells
and used to infect NB4 or COS-7 cells. Forty-eight hours
after transfection, cells were selected with puromycin
(Sigma-Aldrich).
Immunofluorescence assay
The cells, which were treated as described in the text,
were collected onto slides and fixed with 4% paraformal-
dehyde. After permeabilization with methanol and
blocking with 2% (w/v) bovine serum albumin in PBS,
the cells were incubated overnight with the antibody
against p65. Then, the cells were stained with FITC-
labeled anti-rabbit IgG for 1 hour. The cell nuclei were
stained with 4′,6-diamidino-2-phenylindole (DAPI,
Molecular Probes, Eugene, OR). The stained cells were
visualized by fluorescence microscopy (Olympus BX51;
Olympus, Tokyo, Japan).
Patient samples
Patient samples were collected after obtaining informed
consent under a procurement protocol that was ap-
proved by the Ethics Committee of Rui-Jin Hospital af-
filiated to Shanghai Jiao Tong University School of
Medicine, Shanghai, China. Mononuclear cells were iso-
lated from bone marrow of AML patients using Ficoll-
Hypaque liquid (Pharmacia, Piscataway, NJ, USA) and
standard procedures.Statistical analysis
Results were derived from at least three independent ex-
periments and expressed as the mean ± standard devi-
ation. The Student’s t-test was used for statistical analysis.
P < 0.05 was considered to be statistically significant.
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Oridonin-induced stabilization of RARα protein in
leukemia cells
Previously, we reported that oridonin increased RARα
protein levels and antagonized ATRA-induced RARα
loss in leukemia cell lines [23]. To further investigate
this, we used oridonin to treat primary leukemia cells
and the APL cell line, NB4. The effect of oridonin in in-
creasing the levels of RARα protein could be clearly seen
in primary leukemia cells from the bone marrow of three
AML patients (Figure 1A). Clinical information of pa-
tients is shown in Figure 1B. In NB4 cells, oridonin in-
creased RARα protein levels in a dose-dependent
manner (left panel, Figure 1C). When 10 μM of oridonin
was applied for 12 h, the levels of RARα protein became
significantly increased (right panel, Figure 1C). More
interestingly, oridonin failed to modulate the levels of
RARα mRNA in NB4 cells (Figure 1D). Moreover, we
stably transfected RARα-expressing plasmids into COS-
7 cells, and found that oridonin could also increase
levels of the ectopically expressed RARα protein (data
not shown). These data suggest that oridonin regulates
RARα at the post-transcriptional level. In line with this
notion, oridonin delayed the degradation of RARα pro-
tein in NB4 cells treated with oridonin plus cyclohexi-
mide (CHX) compared with cells treated with CHX
alone for different times (Figure 1E). We also deter-
mined the mRNA levels of four known RARα-targeted
genes, RARβ, C/EBP-β, RIG-E, and IRF-1, in NB4 cells
with or without oridonin (10 μM) and/or ATRA (10 nM)
treatment. Consistent with previous reports [25-28],
ATRA treatment alone increased the expression of all four
of these genes, and this expression was significantly en-
hanced by oridonin (Figure 1F). Of note, oridonin alone
also slightly, but significantly, increased the expression of
RIG-E and IRF-1 but not of RARβ and C/EBPα (Figure 1F).
Overall, our results indicate that oridonin can stabilize
RARα protein, which shows transcriptional activity in the
presence of its ligand, ATRA.
Involvement of ROS in oridonin-induced RARα
stabilization
Many studies have shown that oridonin can induce oxi-
dative stress [29,30]. Indeed, oridonin rapidly and transi-
ently increased intracellular reactive oxygen species
(ROS) levels to a moderate but statistically significant
degree in NB4 cells, as assessed by flow cytometric
measurement of the ROS probe, H2DCFDA (Figure 2A).
To investigate whether the increased levels of ROS were
involved in oridonin-induced RARα stabilization, we
treated NB4 cells with 10 μM oridonin for an additional
12 h after pretreatment with or without the ROS scaven-
ger NAC for 1 h, which totally inhibited oridonin-
induced ROS accumulation (left panel, Figure 2B). Ofgreat importance, NAC pretreatment also dramatically
abrogated RARα stabilization by oridonin (right panel,
Figure 2B). This was also true in primary AML cells
(Figure 2C).
We then used H2O2 to treat NB4 cells to determine
the potential role of ROS in RARα stabilization. Intri-
guingly, direct exposure of a low concentration of H2O2
obviously increased RARα protein (Figure 2D–E) but
not mRNA levels (Figure 2F) in a dose- and time-
dependent manner. Furthermore, CHX experiments also
demonstrated that H2O2 delayed the degradation of RARα
protein (Figure 2G). In addition, the specific shRNA-
mediated knockdown of catalase, a key antioxidant en-
zyme that eliminates H2O2 [31], increased endogenous
ROS levels in NB4 cells (left panel, Figure 2H). Accord-
ingly, it also increased the abundance of RARα protein
(right panel, Figure 2H). Together, these data indicate that
a moderately increased level of ROS mediates RARα
stabilization.
Activation of multiple cellular signaling pathways by
oridonin
Next, we addressed how ROS accumulation increases
RARα stabilization. We tested whether ROS cause the
oxidation of RARα protein by treating NB4 cells with
5 μM of H2O2 for 4 h, followed by redox diagonal elec-
trophoresis [32]. The results showed that H2O2 did not
directly target RARα protein to cause its oxidative modi-
fication (Figure 3A). However, converging lines of evi-
dence indicate that ROS, especially H2O2, can actually
function as signaling messengers and drive several as-
pects of cellular signaling [33-35]. We showed that ori-
donin could activate mitogen-activated protein kinases
such as ERK1/ERK2 and p38, as well as JNK1 and JNK2,
as assessed by their increased phosphorylation (Fig-
ure 3B). Of note, levels of phosphorylated ERK1/ERK2
rapidly increased 6 h after oridonin treatment, and then
declined after 12 h, indicating that oridonin activates
ERK1/ERK2 over a short time. More interestingly, orido-
nin could also induce phosphorylation of some import-
ant components of NF-κB signaling, such as inhibitor
kappa B alpha (IκBα) and IKKα/β, indicating that this
compound can activate NF-κB signaling (Figure 3B). In
addition, oridonin also induced phosphorylation of NF-
κB-p65 itself (Figure 3B). Consistently, immunofluores-
cence staining demonstrated that oridonin treatment
induced nuclear localization of NF-κB-p65 (Figure 3C),
supporting the idea that oridonin activates NF-κB
signaling.
Suppression of oridonin-induced RARα stability by
chemical inhibition of NF-κB signaling
To figure out which pathway(s) mediate oridonin-
induced RARα stability, we used specific inhibitors to
Figure 1 Oridonin stabilizes RARα protein in leukemia cells. (A) Primary leukemia cells from three newly diagnosed AML patients were
treated with 10 μM oridonin for 12 h, followed by detection of RARα protein with β-actin as a loading control. (B) Clinical data of the three AML
patients. (C) NB4 cells were treated with the indicated concentrations of oridonin for 12 h (left panel) or with 10 μM oridonin for the indicated
times (right panel), followed by western blot analysis of the RARα protein with β-actin as a loading control. The symbol * denotes a non-specific
protein. (D) NB4 cells were treated as described in panel C, followed by the quantification of RARα mRNA by real-time RT-PCR. (E) NB4 cells were
incubated with 5 μg/mL CHX alone or with 10 μM oridonin for the indicated times. Increased amounts of cell lysates compared with panel A
were loaded and then blotted for the RARα protein with β-actin as a loading control. (F) NB4 cells were treated with 10 μM oridonin and/or 10
nM ATRA for 48 h, and the mRNA levels of the indicated genes were measured by real-time RT-PCR. The data are represented as fold changes
against the control. The symbols * and # represent P values less than 0.05 and 0.01, respectively. All experiments were replicated three times and
gave consistent results.
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Figure 2 ROS are involved in oridonin-induced RARα stabilization. (A) NB4 cells were treated with the indicated concentrations of oridonin
for 12 h (left panel) or with 10 μM oridonin for the indicated times (right panel), followed by detection of ROS levels by flow cytometry. The
symbols * and # represent P values less than 0.05 and 0.01, respectively. (B) After pretreatment with or without 2 mM NAC for 1 h, NB4 cells were
incubated with 10 μM oridonin for 12 h, followed by detection of ROS levels by flow cytometry (left panel) and western blot detection for RARα
protein with β-actin as loading control (right panel). The symbol # represents a P value less than 0.01. (C) Primary AML cells were treated as NB4
cells in the panel B, and the levels of RARα protein were measured. (D, E) NB4 cells were treated with the indicated concentrations of H2O2 for
2 h (D) or with 5 μM H2O2 for the indicated times (E), then the level of RARα protein was assessed. (F) NB4 cells were treated with 5 μM H2O2 for
the indicated times, and RARα mRNA levels were evaluated by real-time RT-PCR. (G) NB4 cells were incubated with 5 μg/mL CHX alone or in
combination with 5 μM H2O2, followed by western blot detection of RARα protein with β-actin as loading control. (H) NB4 cells were infected
with pSIREN-RetroQ-derived retroviruses carrying shRNA specifically against catalase (sh-CAT) or non-specific scrambled shRNA as a control (NC).
Infected cells were assayed for ROS production (left panel) and western blotted for the indicated proteins. The symbol # represents P values less
than 0.01, respectively. All experiments were repeated three times and gave consistent results.
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tion for an additional 12 h. As shown in Figure 4A, pre-
treatment with PD98059 (ERK inhibitor) or SB203580
(p38 inhibitor) did not influence oridonin-induced RARα
stability. In contrast, the JNK inhibitor, SP600125, could
slightly enhance oridonin-increased RARα protein levels.
The effects of these three kinase inhibitors ruled out the
involvement of these pathways in oridonin stabilization
of RARα. However, use of the NF-κB signaling inhibitor,
Bay 11–7082, significantly inhibited oridonin-induced
phosphorylation of IκBα and NF-κB-p65. Interestingly,pre-incubation with Bay 11–7082 antagonized oridonin-
increased RARα protein levels in NB4 cells, which indi-
cated that activation of the NF-κB pathway is required
for oridonin-induced RARα stability (Figure 4B). Similar
results were achieved in AML patient samples (Figure 4C).
In addition, NAC preincubation also blocked oridonin-
induced phosphorylation of IKKα/β, IκBα and NF-κB-p65
(Figure 4D), consistent with its inhibitory effect on
oridonin-stabilized RARα (Figure 2B and C). These data
suggested that oridonin stabilized RARα protein via the
ROS-activated NF-κB pathway.
Figure 3 Oridonin activates multiple cellular signaling pathways. (A) NB4 cells were treated with 5 μM H2O2 for 4 h. RARα protein levels
were examined by redox diagonal electrophoresis, followed by western blot analysis for RARα. (B) NB4 cells were treated with 10 μM oridonin
for the indicated times, and cell lysates were western blotted for the proteins indicated. (C) NB4 cells were treated with 10 μM oridonin for the
indicated times. The intracellular localization of p65 was analyzed by indirect immunofluorescence using anti-p65 antibodies (green). Nuclear DAPI
staining (blue) is also shown. Scale bars represent 20 μm. All experiments were repeated three times and gave consistent results.
Figure 4 NF-κB inhibitor blocks oridonin-induced RARα stability. After pretreatment with and without PD98059, SB203580, SP600125 (A), Bay
11–7082 (B, C), or NAC (D) for 1 h, NB4 cells or primary AML cells were treated with 10 μM oridonin for 12 h, followed by western blot analysis
of proteins as indicated. All experiments were repeated three times and gave consistent results.
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NF-κB for oridonin-induced RARα stability
To confirm that oridonin stabilizes RARα through the
NF-κB pathway, we used NB4/GFP-MAD cells to per-
form further experiments. This engineered cell line sta-
bly expresses the GFP-tagged super-repressor form of
IκΒα, namely IκΒα (A32/36), which confers cellularFigure 5 Oridonin-induced RARα stability requires the activation and
were treated with 10 μM oridonin for 12 h. The intracellular localization of
(blue) for nuclei. Scale bars represent 20 μm. (B, C) NB4/GFP and NB4/GFP-
with 5 μM H2O2 for the times indicated (C), and the cell lysates were weste
pSIREN-RetroQ-derived retroviruses carrying shRNA for p65 or scrambled sh
indicated proteins. (E, F) NB4-NC and NB4-sh-p65 cells were treated with 1
(F), and the cell lysates were western blotted for proteins as indicated. All eresistance to signal-induced phosphorylation and subse-
quent proteasome-mediated degradation of IκΒα, result-
ing in the constitutive suppression of NF-κB activation
by sequestering it in the cytoplasm [36]. As shown in
Figure 5A, the over-expression of IκΒα (A32/36) blocked
oridonin-induced nuclear translocation of p65. As ex-
pected, both oridonin- and H2O2-induced RARα stabilitynuclear translocation of p65. (A) NB4/GFP and NB4/GFP-MAD cells
p65 was analyzed using anti-p65 antibodies (red) with DAPI staining
MAD cells were treated with 10 μM oridonin for 12 h (B) or treated
rn blotted for the indicated proteins. (D) NB4 cells were infected with
RNA as a control, and the cell lysates were western blotted for the
0 μM oridonin for 12 h (E) or with 5 μM H2O2 for the times indicated
xperiments were repeated three times and gave consistent results.
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NB4/GFP cells (Figure 5B and C). Furthermore, we sta-
bly transfected NB4 cells with shRNA specifically against
the p65 subunit of the NF-κB family, which effectively
silenced the expression of p65 but not p50 (Figure 5D).
Notably, p65 knockdown prevented oridonin and H2O2-
induced RARα stability in NB4 cells (Figure 5E and F).
Collectively, these results suggest that the activation and
nuclear translocation of p65 is essential for oridonin to
stabilize RARα.
Promotion of p65 nuclear translocation increases
RARα stability
It is well known that TNFα is a classical activator of NF-
κB signaling; therefore, we investigated the consequence
of TNFα treatment on RARα expression to address
whether oridonin-induced RARα stability is mediated
specifically by ROS-activated NF-κB activation. OurFigure 6 TNFα stabilizes RARα protein by activating NF-κB. (A) NB4 ce
by western blotting for proteins as indicated. (B) NB4 cells were treated wi
using anti-p65 antibodies. (C) NB4 cells with NC or sh-p65 infection were t
for proteins as indicated. (D) NB4/GFP and NB4/GFP-MAD cells were treate
of p65 was analyzed by immunofluorescence. (E) NB4/GFP and NB4/GFP-M
were western blotted for the indicated proteins. All experiments were reperesults showed that TNFα treatment also resulted in a
strong increase in RARα expression together with activa-
tion and nuclear translocation of NF-κB-p65 in NB4
cells (Figure 6A and B). This TNFα-induced RARα sta-
bility could be inhibited by p65 knockdown (Figure 6C).
In addition, the over-expression of IκΒα (A32/36)
blocked the nuclear translocation of p65 and RARα sta-
bility induced by TNFα (Figure 6D and E). All these data
support the idea that translocation of p65 nuclear in-
duces RARα stability.
Discussion
In this study, we report that the natural diterpenoid, ori-
donin, induces a moderate production of cellular ROS
that activates upstream of the NF-κB signaling pathway
to cause nuclear translocation of p65, which is respon-
sible for oridonin-stabilized RARα protein. These find-
ings indicate that moderate oxidative stress induced bylls were treated with 10 ng/mL TNFα for the times indicated, followed
th 10 ng/mL TNFα for 0.5 h, followed by immunofluorescent staining
reated with 10 ng/mL TNFα for 12 h, followed by western blot analysis
d with 10 ng/mL TNFα for 0.5 h, and then the intracellular localization
AD cells were treated with 10 ng/mL TNFα for 12 h. The cell lysates
ated three times and gave consistent results.
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regulate RARα protein stability through the NF-κB sig-
naling pathway, which provides a new perspective of ori-
donin as a candidate anti-neoplastic drug.
The modulation of RARα by ATRA during APL treat-
ment has stimulated considerable interest in RARα metab-
olism and its potential therapeutic mechanism [37]. ATRA
activates RARα signaling with subsequent effects on differ-
entiation, while at the same time steady-state RARα pro-
tein levels are markedly reduced [12]. RARα, as the
receptor for ATRA, is required for its action; therefore,
RARα degradation is thought to be an inbuilt resetting
mechanism to make ATRA signaling self-limiting. There-
fore, it is possible that stabilizing the RARα protein can
optimize this signaling, which indicates that RARα could
be a potential target for cancer therapeutics. Recently, sev-
eral studies have demonstrated that some compounds,
such as lithium chloride (LiCl) [38], granulocyte-colony
stimulating factor [38], STI571 [39], di-tert-butyl-benzohy-
droquinone [40], Pharicin B [15], and oridonin [23], which
are capable of attenuating ATRA-induced loss of RARα
protein, have been shown to enhance ATRA-induced dif-
ferentiation. However, the underlying mechanism of RARα
accumulation has not been fully described. In this work,
we used oridonin as a probe to show that a moderate level
of oxidative stress can stabilize RARα protein through the
nuclear translocation of p65. Further investigation is
needed to test whether this mechanism can be extended
to other small molecules with similar RARα-stabilizing abil-
ity. In addition, because RARα is an essential transcriptional
and homeostatic regulator of a plethora of physiological
processes, numerous investigations have established corre-
lations between down-regulation of RARα and malignant
progression. In addition to APL, this has been observed
in cervical carcinoma [41], skin tumors [42], motor
neuron disease [43], and breast cancer [44]. In this con-
text, stabilizing RARα may permit optimized use of reti-
noids in cancer prevention and treatment, which
warrants further investigation.
It is now widely accepted that a moderate degree of
ROS can play an important role in determining cell fate
through the modulation of cellular signaling and gene
expression [45,46]. For example, elevated but sub-lethal
levels of ROS can modulate the differentiation of various
types of cells, such as hematopoietic cells [47,48], neu-
rons [49], embryonic stem cells [50], osteoclasts [51],
and cardiac stem cells [52]. However, little is known re-
garding the molecular targets of ROS. Here, we found
that moderately increased levels of ROS are crucial for
oridonin-induced RARα stabilization, which may ac-
count for the anti-neoplastic mechanism of oridonin. It
is tempting to suggest that this newly identified mechan-
ism may underlie similar differentiation effects of some
natural diterpenoids. Nevertheless, attention should bepaid to the cell type, as well as to the extent and dur-
ation of ROS increase, as these factors can determine
the precise consequences of the cellular response to oxi-
dative stress. For instance, a relatively high concentra-
tion of H2O2 (0.1 mM) can suppress retinoid signaling
through the proteasomal degradation of RARα [14].
The NF-κB family is a group of transcriptional factors
consisting of p65 (RelA), RelB, c-Rel, p50/p105, and
p52/p100. In the classical NF-κB signaling pathway, the
p50/p65 dimer is sequestered in the cytoplasm by IκΒα.
After stimulation, IκΒα is phosphorylated and conse-
quently degraded through the proteasomal pathway. Thus,
the p50/p65 dimer is released, translocates to the nucleus,
and activates target genes [53]. In this report, we revealed
that oridonin stabilizes RARα protein by inducing nuclear
translocation of p65, which was evidenced by the use of
the ROS scavenger, NAC, the NF-κB inhibitor, Bay 11–
7082, IκΒα (A32/36) over-expression, and p65 knock-
down. Moreover, we tested whether TNFα, a classical
activator of NF-κB signaling, modulates stability of RARα
protein. As expected, TNFα treatment also strongly in-
creased RARα expression, which may account, at least in
part, for TNFα-induced differentiation in some leukemia
cells [54,55]. Previous studies indicated that oridonin
mainly activates the upstream of the NF-κB signaling
pathway, while its inhibitory effect is due to the direct
interference of NF-κB DNA binding activity [56-59].
Leung et al. demonstrated that oridonin decreased the
DNA binding activity of NF-κB without interfering with
p65 translocation [59]. Of note, the exact mechanisms by
which activated NF-κB stabilizes RARα protein require
further investigation.Conclusions
Our results indicate that oridonin stabilizes RARα pro-
tein by increasing the levels of cellular ROS, followed by
activation of the NF-κB signaling pathway. Accordingly,
the NF-κB activator, TNFα, can also increase the stability
of RARα protein. These findings suggest a new mechan-
ism underlying the regulation of RARα protein stability
and shed new light on understanding potential thera-
peutic roles of oridonin in leukemia and other RARα-
related diseases.Abbreviations
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